In this article, combination product consultant Doug Mead provides the rationale and offers guidance for using GenAI tools to search regulatory databases. He shows the benefits for biopharma developers of conducting “precedent research” into previous regulatory pathways and results for similar or related drug delivery product submissions.
- Benchmarking RNA Delivery Performance: Toward Standardized Metrics For Translational Success
- Rethinking Product Development Through Lipid-Based Formulations
- Overcoming Lung Tumor Barriers: Nanoparticle Delivery Strategies For Pulmonary Cancers
- Advances In Endometrial-Targeted Drug Delivery In Women's Health
- RNA Delivery Technologies: Industrial Applications And Emerging Innovations
- Why In Vivo Therapies Fail When We Treat Them Like Ex Vivo Ones
- 4 Opportunities For Advancing Drug Delivery
- In Vivo's Biggest Threat — Comparison To Old Models
ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
NMR And Mass Spectrometry In Pharmaceutical Development
Together, nuclear magnetic resonance (NMR) and MS analysis can definitively identify reference standards, active pharmaceutical ingredients (APIs), or final drug product composition.
-
Best Practices For Ensuring Quality In Biologic Products
New biologic therapies have new challenges in their packaging and delivery systems because of their complexities, higher stability risks, and larger sizes.
-
The Challenges And Opportunities Of Real-World Evidence
The FDA's Real-World Evidence framework addresses challenges in using Real-World Data for regulatory decisions, emphasizing data reliability, bias management, and successful case studies.
-
Faster From Formulation To Fill/Finish
Optimize your speed to clinic by securing a development and aseptic fill/finish partner to support your applications with the right manufacturing equipment, communications, and SOPs.
-
Delivering On GLP-1 Demand: Combining Device And Supply Strategy
Meeting the demand for GLP-1 treatments requires robust and efficient delivery systems. Review how innovative solutions offer customization, streamlined manufacturing, and formulation compatibility.
-
Contract Design And Development Vs. In-House: Finding The Best Fit
Outsourcing medical device R&D to Contract Development Organizations (CDOs) aids innovation, scales resources, and overcomes constraints. Strategic evaluation ensures successful partnerships.
-
Enhancing The Solubility Of High Lipophilicity Drugs Via Spray Drying
A new R&D project shows the solubility and dissolution characteristics of Itraconazole can be improved by helping them maintain an amorphous state after spray drying with selected hydrophilic polymers.
-
Patient Adherence With A Novel Dosage Form
A sprinkle formulation helps patients with tremors or dysphagia take medication more easily, improving adherence, comfort, and care through a novel, FDA-approved oral granule format.
-
AI: The New Partner In Medical Device Development
Involving users in the development process and staying informed about regulatory policies can help ensure AI-powered devices meet the needs of patients and healthcare professionals.
-
Advancements In GLP-1 Analog Formulation: Overcoming Challenges
Oral GLP-1 formulations represent a groundbreaking advance in obesity treatment to offer improved patient comfort and adherence while expanding the therapeutic market.
TOM'S TAKES ON DRUG DELIVERY
TALKING WITH TOM VIDEOCASTS
DELIVERED BY DEGRAZIO
-
4 Opportunities For Advancing Drug Delivery
In this article, Fran DeGrazio identifies four prime opportunities for drug delivery developers to move the dial of innovation into 2026 and beyond. These avenues for advancement include diagnostics, patient tolerability, microdosing, and analytical methodologies.

